July 28, 2014 4:55 AM ET

Biotechnology

Company Overview of Juno Therapeutics Inc.

Company Overview

Juno Therapeutics Inc., a biotechnology company, develops immunotherapy platforms for the treatment of cancer. Its immunotherapy platforms include chimeric antigen receptors, which target cell surface tumor-associated antigens that are expressed on cancer cells; and T-cell receptors, the molecules that are utilized by T-cells to recognize target antigens, as well as detect alterations in intracellular antigens present in cancer cells. The company was incorporated in 2013 and is based in Seattle, Washington.

307 Westlake Avenue North

Suite 300

Seattle, WA 98109

United States

Founded in 2013

Phone:

206-582-1600

Key Executives for Juno Therapeutics Inc.

Co-Founder
Age: 50
Co-Founder and Director
Age: 62
Co-Founder
Co-Founder and Director
Age: 51
Scientific Co-Founder
Compensation as of Fiscal Year 2014.

Juno Therapeutics Inc. Key Developments

Juno Therapeutics Inc. Presents at Washington Biotechnology & Biomedical Association 14th Annual Life Science Innovation Northwest 2014, Jun-20-2014 09:35 AM

Juno Therapeutics Inc. Presents at Washington Biotechnology & Biomedical Association 14th Annual Life Science Innovation Northwest 2014, Jun-20-2014 09:35 AM. Venue: Washington State Convention Center, Seattle, Washington, United States.

Juno Therapeutics Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-02-2014 08:00 AM

Juno Therapeutics Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-02-2014 08:00 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Hans E. Bishop, Co-Founder, Chief Executive Officer and Director.

Juno Therapeutics Inc. Announces Appointments to Its Leadership Team

Juno Therapeutics Inc. announced that Mark W. Frohlich, M.D., has been appointed to be Executive Vice President of R&D. In this role he will oversee the company's scientific, clinical and regulatory activities. Barney Cassidy will serve as General Counsel. He will lead the company's legal affairs including corporate, intellectual property, litigation and compliance matters. Dr. Mark W. Frohlich, M.D. has more than two decades of experience in the field of immuno-oncology. He recently served as the Executive Vice President of R&D and Chief Medical Officer of Dendreon Corp.

Similar Private Companies By Industry

Company Name Region
Cogenics Icoria, Inc. United States
Symphony Dynamo, Inc. United States
Nebraska Cultures, Inc. United States
ThermoGen, Inc. United States
Soluble Therapeutics, LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
April 24, 2014
--
Private Placement
December 3, 2013
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Juno Therapeutics Inc., please visit junotherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.